首页|罗沙司他联合重组人促红素治疗肾性贫血的临床效果及对血脂水平的影响

罗沙司他联合重组人促红素治疗肾性贫血的临床效果及对血脂水平的影响

扫码查看
目的 探讨罗沙司他联合重组人促红素治疗肾性贫血的临床效果及对血脂水平的影响。方法 选取2020年6月至2022年6月南京中医药大学附属苏州市中医医院收治的86例肾性贫血患者为研究对象,随机分为观察组(n=43)和对照组(n=43)。对照组给予重组人促红素治疗,观察组在对照组基础上加用罗沙司他,对比两组治疗后贫血相关指标、铁代谢指标、血脂水平变化及不良反应发生情况。结果 治疗前,两组患者贫血相关指标、铁代谢指标、血脂水平等比较,差异无统计学意义(P>0。05)。治疗后,两组患者的红细胞压积(HCT)、血红蛋白(HGB)、红细胞计数(RBC)、铁蛋白(SF)、转铁蛋白饱和度(TSAT)、转铁蛋白(TRF)水平升高,且观察组高于对照组,差异有统计学意义(P<0。05);两组患者的总胆固醇(TC)、三酰甘油(TG)水平明显降低,且观察组低于对照组,差异有统计学意义(P<0。05)。两组患者的不良反应总发生率比较,差异无统计学意义(P>0。05)。结论 罗沙司他联合重组人促红素治疗肾性贫血可有效改善患者贫血并调节血脂代谢水平,值得临床推广。
Clinical efficacy of roxadustat combined with recombinant human erythropoietin in the treatment of renal anemia and its impact on blood lipid levels
Objective To explore the clinical efficacy of roxadustat combined with recombinant human erythropoietin in the treatment of renal anemia and its impact on blood lipid levels.Methods A total of 86 patients with renal anemia admitted to Suzhou Hospital of Traditional Chinese Medicine Affiliated to Nanjing University of Chinese Medicine from June 2020 to June 2022 were selected as the study subjects,and randomly divided into an observation group(n=43)and a control group(n=43).The control group was treated with recombinant human erythropoietin,while the observation group was treated with roxadustat in addition to the control group.The anemia related indicators,iron metabolism indicators,changes in blood lipid levels,and adverse reactions were compared between the two groups after treatment.Results Before treatment,there was no statistically significant difference in anemia related indicators,iron metabolism indicators,and blood lipid levels between the two groups of patients(P>0.05).After treatment,the levels of hematocrit(HCT),hemoglobin(HGB),red blood cell count(RBC),ferritin(SF),transferrin saturation(TSAT),and transferrin(TRF)in the two groups of patients increased,and the observation group was higher than the control group,with statistically significant differences(P<0.05).The total cholesterol(TC)and triglyceride(TG)levels of the two groups of patients were significantly reduced,and the observation group was lower than the control group,with statistically significant differences(P<0.05).There was no statistically significant difference in the total incidence of adverse reactions between the two groups of patients(P>0.05).Conclusion The combination of roxadustat and recombinant human erythropoietin can effectively improve anemia and regulate lipid metabolism in patients with renal anemia,and is worthy of clinical promotion.

RoxadustatRecombinant human erythropoietinRenal anemiaIron metabolismLipid metabolism

石志坚、王兴明

展开 >

南京中医药大学附属苏州市中医医院药剂科,江苏苏州 215000

罗沙司他 重组人促红素 肾性贫血 铁代谢 血脂代谢

2024

中国医药科学
海峡两岸医药卫生交流协会 二十一世纪联合创新(北京)医药科学研究院

中国医药科学

影响因子:1.083
ISSN:2095-0616
年,卷(期):2024.14(6)
  • 17